The stock is down 3%, or $2.81, to $80.26 in premarket trading.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
- Novo Nordisk price target raised to DKK 798 from DKK 795 at Guggenheim
- Insulin prices have dropped but some poor patients are paying more, NYT says
- Novo Nordisk Advances Share Repurchase Programme